Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:48:22.734Z.
Calculation as of: 2026-10-06T19:48:22.734Z.
Quote observation: 2026-10-06T19:45:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 347a41eedf46a91d1f1a35dde2c997a021a555167078676fef94c90a8032fb0d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
MiniMed Group, Inc. Common Stock
Market Cap
$5.49B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.22B
Price/OCF Ratio
N/A
TTM Avg
11.41
3Y Avg
54.55
5Y Avg
54.55
Market Cap
$5.20B
Price/OCF Ratio
56.07
TTM Avg
90.64
3Y Avg
90.64
5Y Avg
90.64
Market Cap
$5.20B
Price/OCF Ratio
17.78
TTM Avg
18.39
3Y Avg
16.81
5Y Avg
18.04
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. Common Stock (MMED) | $5.49B | N/A | N/A | N/A | N/A |
| RadNet, Inc. (RDNT)vs › | $5.51B | 17.38 | 17.73 | 17.23 | 13.87 |
| CG Oncology Inc. (CGON)vs › | $5.59B | N/A | N/A | N/A | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.29B | N/A | 7.44 | 7.44 | 7.44 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.22B | N/A | 11.41 | 54.55 | 54.55 |
| Doximity, Inc. (DOCS)vs › | $5.22B | 17.03 | 20.94 | 34.29 | 45.54 |
| Travere Therapeutics, Inc. (TVTX)vs › | $5.20B | 56.07 | 90.64 | 90.64 | 90.64 |
| Sotera Health Company (SHC)vs › | $5.20B | 17.78 | 18.39 | 16.81 | 18.04 |
| Kodiak Sciences Inc. (KOD)vs › | $5.82B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.82B | N/A | 1.10 | 1.10 | 1.10 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
